Hawkins, Inc. Reports Second‑Quarter Fiscal 2026 Results

HWKN
October 30, 2025

Hawkins, Inc. reported second‑quarter fiscal 2026 revenue of $280.4 million, a 14% year‑over‑year increase from $247.0 million, and net income of $22.6 million, or $1.08 per diluted share, compared with $24.1 million and $1.16 in the same quarter a year earlier. Revenue was slightly below consensus estimates of $284.42 million to $290.1 million, and earnings per share missed the consensus estimate of $1.24 (or $1.20) by $0.16.

The Water Treatment segment generated $150.9 million in sales, up 21% from $124.5 million, and achieved a gross profit of $43.3 million, a 20% increase to 29% of sales. Industrial Solutions sales rose 11% to $56.6 million, with gross profit of $8.9 million, a 9% increase to 16% of sales. Food & Health Sciences sales grew 2% to $72.9 million, but gross profit fell 4% to $15.5 million, or 21% of sales, due to lower selling prices amid competitive pressure.

Gross profit for the quarter climbed 12% to $67.6 million, up from $60.2 million a year earlier, and adjusted EBITDA increased 9% to $50.4 million from $46.3 million. Hawkins repaid $20 million on its revolving credit facility, reducing total debt to $279.0 million and raising the trailing 12‑month pro‑forma adjusted EBITDA leverage ratio to 1.53× from 0.86×.

The company completed the WaterSurplus acquisition in the first quarter of fiscal 2026. Integration costs are expected to add $17 million of annualized expense in 2026, offsetting some earnings growth, but management expects the acquisition to become accretive in fiscal 2027 and to unlock high‑margin sales opportunities.

Hawkins declared a regular quarterly cash dividend of $0.19 per share, payable November 28 2025, underscoring its commitment to shareholder returns.

The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.